Business Description
Vyome Holdings Inc. is a Cambridge, Massachusetts-based pharmaceutical company focused on developing treatments for inflammatory and rare diseases. Its most advanced drug candidate, VT-1953, is currently in Phase 2 trials as a topical gel for bacterial eye infections, while VT-1908 is being developed as an eye drop to address inflammatory eye conditions. The company is also progressing VB-1953 through Phase 2 trials for inflammatory acne and is building a pipeline of next-generation antifungal treatments through a partnership with Sun Pharma Laboratories Limited.
